Organogenesis Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Net Product Revenue Quarterly36.3MTarget: 270000000 to 310000000
Advanced Wound Care Revenue Quarterly29.5M
Operating Expense Reduction (ex-COGS) Quarterly25.0Target: 25% year-over-year reduction for FY 2026
Watch Items
- CMS Skin-Substitute Reimbursement PolicyTrigger: Further restrictive local coverage determinations (LCDs) or national payment changes by Medicare administrative contractors.Action: Re-evaluate wound care sales forecasts and adjust commercial channel strategy.
- FDA Review of ReNu BLATrigger: FDA acceptance of the BLA filing or issuance of a Complete Response Letter (CRL).Action: Update long-term pipeline valuation models and commercial launch readiness plans.
Research as of 19 Jun 2026